Prana Doses First Patient in the "IMAGINE" Phase II Alzheimer's Disease Trial
Biotechnology (NASDAQ: PRAN ) today announced that the first patient has been dosed in the "IMAGINE Trial" -- 12 month Phase II Imaging trial testing PBT2, the Company's drug in development for Alzheimer's Disease.
In the "IMAGINE trial" PBT2, a drug that significantly changed Abeta levels in spinal fluid and significantly improved the cognition of Alzheimer's Disease patients in an earlier 12 week clinical trial, is now being assessed in a 12 month study for its effects on the distribution of amyloid in the brain and cognitive and functional improvement. The data on PBT2 from the preceding clinical trial has been published in Lancet Neurology and Journal of Alzheimer's Disease.(1) (2) (3)
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.